Iovance Biotherapeutics Inc [NASDAQ: IOVA] stock went on a downward path that fall over -4.33% on Wednesday, amounting to a one-week price decrease of less than -10.08%.
Over the last 12 months, IOVA stock rose by 22.91%. The one-year Iovance Biotherapeutics Inc stock forecast points to a potential upside of 63.15. The average equity rating for IOVA stock is currently 1.31, trading closer to a bullish pattern in the stock market.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for the stock reached $2.60 billion, with 256.14 million shares outstanding and 223.62 million shares in the current float. Compared to the average trading volume of 6.10M shares, IOVA stock reached a trading volume of 8775854 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Iovance Biotherapeutics Inc [IOVA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IOVA shares is $25.18 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IOVA stock is a recommendation set at 1.31. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Goldman have made an estimate for Iovance Biotherapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on November 20, 2023. While these analysts kept the previous recommendation, Barclays dropped their target price from $40 to $18. The new note on the price target was released on September 18, 2023, representing the official price target for Iovance Biotherapeutics Inc stock. Previously, the target price had yet another raise from $11 to $17, while Wells Fargo kept a Overweight rating on IOVA stock.
The Average True Range (ATR) for Iovance Biotherapeutics Inc is set at 0.72, with the Price to Sales ratio for IOVA stock in the period of the last 12 months amounting to 1366.75. The Price to Book ratio for the last quarter was 3.82, with the Price to Cash per share for the same quarter was set at 1.27.
IOVA Stock Performance Analysis:
Iovance Biotherapeutics Inc [IOVA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -10.08. With this latest performance, IOVA shares dropped by -22.86% in over the last four-week period, additionally plugging by 67.81% over the last 6 months – not to mention a rise of 22.91% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IOVA stock in for the last two-week period is set at 26.06, with the RSI for the last a single of trading hit 17.91, and the three-weeks RSI is set at 32.22 for Iovance Biotherapeutics Inc [IOVA]. The present Moving Average for the last 50 days of trading for this stock 12.37, while it was recorded at 9.92 for the last single week of trading, and 8.69 for the last 200 days.
Insight into Iovance Biotherapeutics Inc Fundamentals:
Iovance Biotherapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.42 and a Current Ratio set at 4.63.
Iovance Biotherapeutics Inc [IOVA] Institutonal Ownership Details
The top three institutional holders of IOVA stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.4983%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $200.69 billion in IOVA stocks shares; and BERKSHIRE HATHAWAY INC, currently with $174.35 billion in IOVA stock with ownership which is approximately 5.8386%.
